Op-T

Op-T is a Japanese biotechnology company specializing in the development of next-generation regulatory T cell (Treg) therapies for autoimmune diseases and organ transplantation. Founded on the pioneering research of Dr. Shimon Sakaguchi at Osaka University, the company utilizes a proprietary platform to generate antigen-specific Tregs that can suppress unwanted immune responses with high precision. Their approach aims to restore immune tolerance without the need for systemic immunosuppression, potentially offering curative treatments for chronic conditions. The company's pipeline includes programs for Type 1 Diabetes and Multiple Sclerosis, currently in the pre-clinical stage. Op-T is backed by prominent venture capital firms and maintains strong ties with academic research centers in Japan.